风湿病学中生物制剂和靶向合成疾病调节药物的长期安全性。

IF 5.2 2区医学 Q1 RHEUMATOLOGY

Current opinion in rheumatology Pub Date : 2023-12-21 DOI:10.1097/bor.0000000000000995

Kaia Barth, Harsimrat Gill, Namrata Singh

{"title":"风湿病学中生物制剂和靶向合成疾病调节药物的长期安全性。","authors":"Kaia Barth, Harsimrat Gill, Namrata Singh","doi":"10.1097/bor.0000000000000995","DOIUrl":null,"url":null,"abstract":"The landscape for treatment of rheumatic diseases is ever evolving, with several new drugs recently approved across diseases and more in the pipeline. This timely review aims to highlight the latest literature on long-term safety profiles of salient established and emerging biologic (b) and targeted synthetic (ts) disease modifying antirheumatic drugs (DMARDs).","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":null,"pages":null},"PeriodicalIF":5.2000,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term safety of biologic and targeted synthetic disease modifying drugs in rheumatology.\",\"authors\":\"Kaia Barth, Harsimrat Gill, Namrata Singh\",\"doi\":\"10.1097/bor.0000000000000995\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The landscape for treatment of rheumatic diseases is ever evolving, with several new drugs recently approved across diseases and more in the pipeline. This timely review aims to highlight the latest literature on long-term safety profiles of salient established and emerging biologic (b) and targeted synthetic (ts) disease modifying antirheumatic drugs (DMARDs).\",\"PeriodicalId\":11145,\"journal\":{\"name\":\"Current opinion in rheumatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2023-12-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current opinion in rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/bor.0000000000000995\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/bor.0000000000000995","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

风湿性疾病的治疗形势不断变化，最近批准了几种治疗各种疾病的新药，还有更多新药正在研发中。这篇及时的综述旨在重点介绍有关已上市和新上市的生物制剂（b）和靶向合成药物（ts）改变疾病抗风湿药（DMARDs）长期安全性的最新文献。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Long-term safety of biologic and targeted synthetic disease modifying drugs in rheumatology.

The landscape for treatment of rheumatic diseases is ever evolving, with several new drugs recently approved across diseases and more in the pipeline. This timely review aims to highlight the latest literature on long-term safety profiles of salient established and emerging biologic (b) and targeted synthetic (ts) disease modifying antirheumatic drugs (DMARDs).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current opinion in rheumatology 医学-风湿病学

CiteScore

9.70

自引率

2.00%

发文量

审稿时长

6-12 weeks

期刊介绍： A high impact review journal which boasts an international readership, Current Opinion in Rheumatology offers a broad-based perspective on the most recent and exciting developments within the field of rheumatology. Published bimonthly, each issue features insightful editorials and high quality invited reviews covering two or three key disciplines which include vasculitis syndromes, medical physiology and rheumatic diseases, crystal deposition diseases and rheumatoid arthritis. Each discipline introduces world renowned guest editors to ensure the journal is at the forefront of knowledge development and delivers balanced, expert assessments of advances from the previous year.